What is FluidPath?
FluidPath is a platform dedicated to improving the effectiveness of workplace drug testing programs.
We are not a laboratory, a collection provider, or a test manufacturer—and we are not here to sell testing services.
Instead, FluidPath serves as a central hub for data, education, and practical resources designed to help the industry perform better in its efforts to improve real-world detection effectiveness.
By bringing visibility to matrix performance through a system sensitivity lens, highlighting structural barriers, and supporting those involved across the testing ecosystem, FluidPath helps translate insight into action.
This includes not only analysis and thought leadership, but also accessible tools and training that reduce friction, improve consistency, and support better outcomes across the system.
The Future of Drug Testing Isn’t a New Test.
It’s a Better System.
Urine testing has long been the standard in workplace drug testing programs—but its real-world detection performance is often assumed, not measured.
Our mission is simple
To improve workplace safety by increasing visibility into real-world performance, accelerating the shift beyond legacy processes, and enabling more efficient, modern approaches across the workplace drug testing industry.
The Problem:
An Unchallenged Assumption
Workplace drug testing programs are widely assumed to be performing as intended.
But that assumption is rarely tested.
Detection begins before the laboratory, where collection design, donor behavior, and opportunities to avoid detection all influence whether drug use is ultimately captured.
System sensitivity reflects how effectively a program identifies drug use under these real-world conditions.
In practice, individuals respond to incentives. When testing environments allow opportunities to avoid detection, behavior adapts accordingly.
This dynamic can create meaningful differences in detection outcomes across testing approaches—differences that are often invisible in standard program reporting.
As a result, programs may appear effective—while failing to see what’s really going on.
Most programs are assumed to be effective based on cost and test results—not real-world detection effectiveness or risk reduction.
Donor behavior adapts to perceived opportunities to avoid detection-and consequence.
Collection conditions directly influence whether drug use is captured.
Detection gaps can exist – without being visible in standard reporting.
The Evidence
Explore the data behind real-world detection performance.
Non-DOT comparative data: Real-world program comparisons show significantly higher detection rates with oral fluid across similar populations.
A line in the sand.
DOT paired data: Side-by-side testing within identical applicant populations reveals measurable detection gaps under controlled conditions. Same donors, same time – different outcomes.
Quest DTI analysis: National datasets across millions of tests reinforce consistent differences in detection across specimen types. Large-scale trends support real-world findings.
The Goal
Reducing the Detection Gap
If differences in detection are driven in part by behavioral responses to opportunity, then reducing those opportunities becomes the path to improving outcomes.
Oral fluid testing changes the conditions under which specimens are collected—limiting opportunities for circumvention and strengthening the connection between drug use and detection.
By reducing the ability to avoid detection, oral fluid can improve system sensitivity and provide a clearer view of real-world drug use.
If the input is compromised, the system can’t perform—
no matter what happens downstream.
Incentives to avoid detection drive behavioral adaptation.
Detection gaps emerge when opportunities to avoid detection exist.
Closing circumvention pathways reduces the opportunity to avoid detection.
When opportunity is reduced, the detection gap narrows.
The Opportunity
Improving system sensitivity doesn’t just enhance detection—it creates opportunity across the entire testing ecosystem.
- Direct observation reduces opportunities for substitution and adulteration.
- Collection occurs in a more controlled and observable environment.
- Detection is more closely aligned with recent drug use.
- Detection starts with the specimen – quality in determines quality out.
The Missing Piece
Why Opportunity Hasn’t Scaled
EMPLOYERS
Cost Visibility Gap
Programs are typically evaluated on cost per test—not cost per detection—making higher-performing approaches appear more expensive without clear ROI visibility.
COLLECTION SITES
Device Cost & Inventory Burden
Collection sites are often required to purchase and manage oral fluid devices upfront—creating financial risk, inventory management challenges, and uncertainty around reimbursement.
LABORATORIES
Economic & Operational Friction
Transitioning from urine to oral fluid introduces margin uncertainty, operational complexity, and added logistical considerations around device handling—creating resistance to change despite potential performance benefits.
TPAs
Program Inertia
Programs are designed around established workflows and client expectations, making meaningful changes difficult without clear, system-wide alignment.
REGULATORS
Policy Lag
Regulatory frameworks ensure consistency, but often evolve more slowly than real-world performance insights, delaying broader adoption of improved approaches.